Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 6, 2009

Mitsubishi Tanabe Signs On Affectis for Discovery Work for Antidepressants

  • Mitsubishi Tanabe Pharma (MTPC) will use Affectis Pharmaceuticals’ behavioral pharmacology expertise and technology in its drug discovery efforts. Affectis will receive research fees and is eligible to developmental milestones. 
     
    MTPC’s ongoing drug discovery program is reportedly based on a novel depression target that Affectis helped validate in a previous collaboration. The deal, which was inked in February 2005, covered the use of Affectis’ Behavioural Interference™ platform.

    Under the new agreement, MTPC will continue to utilize this technology and Affectis’ expertise. Affectis has two antidepressant discovery programs and one Phase II candidate for depression.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »